Abstract 294P
Background
We aimed to assess the safety and preliminary efficacy of cisplatin every 3 weeks in concurrent chemoradiation in cervical cancer in the era of modern radiotherapy techniques such as IMRT/VMAT.
Methods
This is a single-arm phase 2 clinical trial which included patients with stage IB3-IVA cervical cancer at Vietnam National Cancer Hospital. Neuroendocrine carcinoma was excluded. Patients were treated with definitive chemoradiotherapy with cisplatin 75mg/m2, day 1, 22 and 43 concurrently with external beam radiotherapy and brachytherapy. Treatment completion rate, response rate and toxicities were assessed.
Results
A total of 38 patients were included, with a mean age of 53.3 years (range 33-71). The mean tumor size was 4.31 ± 0.87 cm. Stage IB3, II and III accounted for 2.6%, 44.7% and 52.6% respectively. Thirty-seven patients (97.3%) completed planned treatment protocol, with the mean total time of radiation therapy of 49.8 ± 5.9 days. At 1 month after treatment, the complete clinical response rate was 84.2% (32/38 patients), partial response was recorded in 4 patients with stage IIIC1 and 2 patients with stage IIB. Among these 6 patients, 4 cases had complete response at 3 months after treatment. Grade 3 toxicity included neutropenia (15.8%) and vomiting (13.2%), no febrile neutropenia or life-threatening toxicities were recorded.
Conclusions
Concurrent chemoradiation with cisplatin every 3 weeks is a safe and feasible therapy for locally advanced cervical cancer and might be suitable for places with shortage of facilities and human resources in chemotherapy infusion unit. A larger randomized controlled trial should be done to confirm the efficacy of the 3-weekly schedule.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract